OcuTherm® Dry Eye Clinical Study

OcuTherm® Dry Eye Clinical Study

OcuTherm®
Dry Eye Clinical Study

Powerful Symptom Reduction

Results from the 4-week OcuTherm® clinical study are illustrated in the bar graph. All data were published in the journal Investigative Ophthalmology and Visual Science (see ref. 1 below).

High rates of user satisfaction, ease of use, sustained heat duration, and use of moisturized heat are the factors most likely to have contributed to the positive outcomes (see refs. 2-5 below).

Details and Methods: 30 adult subjects were studied. All had persistent symptoms despite previous dry eye therapy, and were diagnosed with dry eye syndrome related to Meibomian gland dysfunction (MGD) and/or anterior blepharitis. All subjects were provided with OcuTherm kits, and instructed to apply OcuTherm moisturized-heat therapy. Those subjects currently using eye drops and/or oral supplements (e.g., artificial tears, Restasis®, Omega-3 supplements, etc.), were allowed to continue during the study.

Symptoms were evaluated at 0, 2, and 4 weeks using the Ocular Surface Disease Index (OSDI) scale, with the results shown in the bar graph (see ref. 6 below). Usage diaries and selected questionnaires were also used.

Powerful Symptom Reduction

Results from the 4-week OcuTherm® clinical study
are shown and discussed below.

Results were published in Investigative Ophthalmology and Visual Science (see ref. 1 below).

High rates of user satisfaction, ease of use, sustained heat duration, and use of moisturized heat are the factors most likely to have contributed to the positive outcomes (see refs. 3-6 below).

Details and Methods: 30 adult subjects were studied. All had persistent symptoms despite previous dry eye therapy, and were diagnosed with dry eye syndrome related to Meibomian gland dysfunction (MGD) and/or anterior blepharitis. All subjects were provided with OcuTherm kits, and instructed to apply OcuTherm moisturized-heat therapy. Those subjects currently using eye drops and/or oral supplements (e.g., artificial tears, Restasis®, Omega-3 supplements, etc.), were allowed to continue during the study.

Symptoms were evaluated at 0, 2, and 4 weeks using the Ocular Surface Disease Index (OSDI) scale, with the results shown in the bar graph (see ref. 2 below). Usage diaries and selected questionnaires were also used.

Powerful Symptom Reduction

Results from the 4-week OcuTherm® clinical study are shown and discussed below.

Results were published in Investigative Ophthalmology and Visual Science (see ref. 1 below).

High rates of user satisfaction, ease of use, sustained heat duration, and use of moisturized heat are the factors most likely to have contributed to the positive outcomes (see refs. 3-6 below).

Details and Methods: 30 adult subjects were studied. All had persistent symptoms despite previous dry eye therapy, and were diagnosed with dry eye syndrome related to Meibomian gland dysfunction (MGD) and/or anterior blepharitis. All subjects were provided with OcuTherm kits, and instructed to apply OcuTherm moisturized-heat therapy. Those subjects currently using eye drops and/or oral supplements (e.g., artificial tears, Restasis®, Omega-3 supplements, etc.), were allowed to continue during the study.

Symptoms were evaluated at 0, 2, and 4 weeks using the Ocular Surface Disease Index (OSDI) scale, with the results shown in the bar graph (see ref. 2 below). Usage diaries and selected questionnaires were also used.

our products

References

1Chinwuba I, Tsui E, Mitry M, et al. The OcuTherm System, a Novel At-Home Eyelid Thermal Treatment Device – A 4-Week Clinical Study. Presented at the Association of Research in Vision and Ophthalmology (ARVO). Published in: Invest. Ophthalmol. Vis. Sci. 2017;58(8):2684. Click here to view the article.

2Geerling G, Tauber J, Baudouin C, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2011;52:2050–2064.

3 Murakami DK, Blackie CA, Korb DR. All Warm Compresses Are Not Equally Efficacious. Optom Vis Sci. 2015 Sep;92(9):e327-33.

4Blackie CA, Solomon JD, Greiner JV, et al. Inner eyelid surface temperature as a function of warm compress methodology. Optom Vis Sci. 2008 Aug;85(8):675-83.

5Olson MC, Korb DR, Greiner JV. Increase in tear film lipid layer thickness following treatment with warm compresses in patients with meibomian gland dysfunction. Eye Contact Lens. 2003;29:96–99.

6Dougherty BE, Nichols JJ, and Nichols KK. Rasch Analysis of the Ocular Surface Disease Index (OSDI). Invest Ophthalmol Vis Sci. 2011;52:8630–8635.

1Chinwuba I, Tsui E, Mitry M, et al. The OcuTherm System, a Novel At-Home Eyelid Thermal Treatment Device – A 4-Week Clinical Study. Presented at the Association of Research in Vision and Ophthalmology (ARVO). Published in: Invest. Ophthalmol. Vis. Sci. 2017;58(8):2684. Click here to view the article.

2Geerling G, Tauber J, Baudouin C, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2011;52:2050–2064.

3 Murakami DK, Blackie CA, Korb DR. All Warm Compresses Are Not Equally Efficacious. Optom Vis Sci. 2015 Sep;92(9):e327-33.

4Blackie CA, Solomon JD, Greiner JV, et al. Inner eyelid surface temperature as a function of warm compress methodology. Optom Vis Sci. 2008 Aug;85(8):675-83.

5Olson MC, Korb DR, Greiner JV. Increase in tear film lipid layer thickness following treatment with warm compresses in patients with meibomian gland dysfunction. Eye Contact Lens. 2003;29:96–99.

6Dougherty BE, Nichols JJ, and Nichols KK. Rasch Analysis of the Ocular Surface Disease Index (OSDI). Invest Ophthalmol Vis Sci. 2011;52:8630–8635.

1Chinwuba I, Tsui E, Mitry M, et al. The OcuTherm System, a Novel At-Home Eyelid Thermal Treatment Device – A 4-Week Clinical Study. Presented at the Association of Research in Vision and Ophthalmology (ARVO). Published in: Invest. Ophthalmol. Vis. Sci. 2017;58(8):2684. Click here to view the article.

2Geerling G, Tauber J, Baudouin C, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2011;52:2050–2064.

3 Murakami DK, Blackie CA, Korb DR. All Warm Compresses Are Not Equally Efficacious. Optom Vis Sci. 2015 Sep;92(9):e327-33.

4Blackie CA, Solomon JD, Greiner JV, et al. Inner eyelid surface temperature as a function of warm compress methodology. Optom Vis Sci. 2008 Aug;85(8):675-83.

5Olson MC, Korb DR, Greiner JV. Increase in tear film lipid layer thickness following treatment with warm compresses in patients with meibomian gland dysfunction. Eye Contact Lens. 2003;29:96–99.

6Dougherty BE, Nichols JJ, and Nichols KK. Rasch Analysis of the Ocular Surface Disease Index (OSDI). Invest Ophthalmol Vis Sci. 2011;52:8630–8635.